The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Biodexa Pharmaceuticals's current ratio for the quarter that ended in Dec. 2025 was 2.03.
Biodexa Pharmaceuticals has a current ratio of 2.03. It generally indicates good short-term financial strength.
The historical rank and industry rank for Biodexa Pharmaceuticals's Current Ratio or its related term are showing as below:
STU:5MP2'
s Current Ratio Range Over the Past 10 Years
Min: 1.26 Med: 2.33 Max: 6.39
Current: 2.03
During the past 13 years, Biodexa Pharmaceuticals's highest Current Ratio was 6.39. The lowest was 1.26. And the median was 2.33.
STU:5MP2's Current Ratio is ranked worse than 68.1% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs STU:5MP2: 2.03
Biodexa Pharmaceuticals (STU:5MP2) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Biodexa Pharmaceuticals Current Ratio Related Terms
Biodexa Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:5MP2 vs CASIF, OGEN, ELOX: Current Ratio Comparison
For the Biotechnology subindustry, Biodexa Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biodexa Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biodexa Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Biodexa Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biodexa Pharmaceuticals (STU:5MP2) has a Current Ratio of 2.03 as of Dec. 2025. This is 13% below median its historical median of 2.33. Over the past decade, Biodexa Pharmaceuticals' Current Ratio has ranged from 1.26 to 6.39. According to the industry distribution chart, Biodexa Pharmaceuticals ranks #965 out of 1417 companies in the Biotechnology industry, placing it in the top 68.1%.
Is Biodexa Pharmaceuticals' Current Ratio too high?
Biodexa Pharmaceuticals' current Current Ratio of 2.03 is 13% below median its 10-year median of 2.33. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 6.39. The Biotechnology industry median Current Ratio is 3.89. Biodexa Pharmaceuticals' value of 2.03 is 47.8% below this industry median. Based on the distribution chart, Biodexa Pharmaceuticals ranks #965 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Current Ratio compare to CASIF and OGEN?
According to the Biotechnology industry distribution chart, Biodexa Pharmaceuticals ranks #965 out of 1417 companies for Current Ratio. This places Biodexa Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 3.89. Biodexa Pharmaceuticals' value of 2.03 is 47.8% below this benchmark. Historically, Biodexa Pharmaceuticals' own Current Ratio has ranged from 1.26 to 6.39 over the past decade. While the company's 10-year median is 2.33 vs. the industry median of 3.89, Biodexa Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biodexa Pharmaceuticals's current Current Ratio of 2.03 is 47.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biodexa Pharmaceuticals's current Current Ratio is 2.03, which is 13% below median its own 10-year median of 2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (STU:5MP2) has a current Current Ratio of 2.03. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current Current Ratio is 2.03, which is 13% below median its 10-year median of 2.33 and 47.8% below the Biotechnology industry median of 3.89. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current Current Ratio is 2.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?
Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued.
The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.
Key valuation signals for STU:5MP2:
Current Ratio: 2.03 (13% below median its 10-year median of 2.33)
GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
Industry Position: 47.8% below the Biotechnology median (#965 of 1417)
No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
10GF Score
Get the complete analysis for STU:5MP2
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5MP2 has been successfully added to your 
